Lijin Li

机构：Washington University in St. Louis · ORCID：0000-0002-5445-3158

发表论文 50 篇 · 总被引 1416 次 · h-index 15

代表论文

• cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity (2020 · Nature · 被引 621)
• Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity (2017 · Cancer Immunology Research · 被引 92)
• Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients (2024 · Genome Medicine · 被引 88)
• Safety and Preliminary Evidence of Biologic Efficacy of a Mammaglobin-A DNA Vaccine in Patients with Stable Metastatic Breast Cancer (2014 · Clinical Cancer Research · 被引 88)
• Cross-dressed CD8α + /CD103 + dendritic cells prime CD8 + T cells following vaccination (2012 · Proceedings of the National Academy of Sciences · 被引 80)
• Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation (2021 · Genome Medicine · 被引 68)